Publications
2025
Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver.
van den Berg, S., Attwood, M. G. L., Griffin, P., Sassen, S. D. T., Muller, A. E., Raaphorst, M. N., . . . MacGowan, A. P. (2025). Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver.. The Journal of antimicrobial chemotherapy, dkae469. doi:10.1093/jac/dkae469
2024
Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.
Pardos, S. L., Hope, W., Kotsaki, A., Das, S., Giamarellos-Bourboulis, E. J., Kontopoulouk, T., . . . MacGowan, A. P. (2024). Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.. The Journal of antimicrobial chemotherapy, 79(12), 3303-3312. doi:10.1093/jac/dkae363
<i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.
Dubey, V., Farrington, N., Harper, N., Johnson, A., Horner, I., Stevenson, A., . . . Hope, W. (2024). <i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.. Antimicrobial agents and chemotherapy, 68(10), e0022224. doi:10.1128/aac.00222-24
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections.
Hameed P, S., Kotakonda, H., Sharma, S., Nandishaiah, R., Katagihallimath, N., Rao, R., . . . V, B. (2024). BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections.. Nature communications, 15(1), 8202. doi:10.1038/s41467-024-52557-2
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.
Das, S., Riccobene, T., Carrothers, T. J., Wright, J. G., MacPherson, M., Cristinacce, A., . . . Raber, S. (2024). Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.. European journal of clinical pharmacology, 80(4), 529-543. doi:10.1007/s00228-023-03609-x
Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.
Farrington, N., Dubey, V., Johnson, A., Horner, I., Stevenson, A., Unsworth, J., . . . Darlow, C. A. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.. mBio, 15(2), e0316523. doi:10.1128/mbio.03165-23
2022
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323